Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Non-Current Liabilities (2016 - 2025)

Capricor Therapeutics has reported Total Non-Current Liabilities over the past 15 years, most recently at $14.3 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $14.3 million for Q4 2025, up 258.68% from a year ago — trailing twelve months through Dec 2025 was $14.3 million (up 258.68% YoY), and the annual figure for FY2025 was $14.3 million, up 258.68%.
  • Total Non-Current Liabilities for Q4 2025 was $14.3 million at Capricor Therapeutics, down from $14.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CAPR hit a ceiling of $26.0 million in Q1 2022 and a floor of $194603.0 in Q2 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $5.3 million (2021), compared with a mean of $8.6 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 660.79% in 2022 and later tumbled 95.6% in 2025.
  • Capricor Therapeutics' Total Non-Current Liabilities stood at $5.8 million in 2021, then skyrocketed by 152.57% to $14.7 million in 2022, then tumbled by 66.97% to $4.9 million in 2023, then fell by 17.9% to $4.0 million in 2024, then surged by 258.68% to $14.3 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $14.3 million (Q4 2025), $14.4 million (Q3 2025), and $194603.0 (Q2 2025) per Business Quant data.